Consider Our Overview Before Taking a Position in VERU

By Harris Dyer • Saturday, December 10 15:31 • Permanent Link

Shares of Veru have moved -6.2% Friday, and are now trading at a price of $5.47. In contrast, the S&P 500 index saw a -0.7% change and the Dow Industrial Average posted a -0.6% performance. Today's trading volume is 3,073,258 compared to the stock's average volume of 4,939,223.

Veru Inc., a biopharmaceutical company, focuses on developing medicines for the management of COVID-19, and breast and prostate cancers. Based in Miami, United States the company has 233 full time employees and a market cap of $441,008,352. The company is now trading -65.27% away from its average analyst target price of $15.75 per share. The 4 analysts following the stock have set target prices ranging from $3 to $22, and on average give Veru a rating of buy.

Over the last year, VERU shares have gone down by -10.5%, which represents a difference of 5.3% when compared to the S&P 500. The stock's 52 week high is $24.55 per share and its 52 week low is $4.34. Based on Veru's average gross margin growth of 4.6% over the last four years, its core business remains strong and the stock price may recover in the long term.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.